Abstract
As part of a clinical trial, photorefractive keratectomy using the VISX 2015 193-nm excimer laser was performed on 91 healthy eyes of 91 patients. Preoperative refractive errors (spherical equivalent) ranged from -1.00 to - 7.50 diopters (mean, -4.16 ± 1.41 diopters). No patient had more than 1 diopter of refractive astigmatism. Six months postoperatively, the average residual refractive error was +0.09 ± 0.63 diopters (range, -2.13 to +1.63 diopters). Correction within 1 diopter of that attempted was attained in 85 eyes (93%). Uncorrected visual acuity of 20/40 or better was attained in 86 eyes (95%) and was 20/25 or better in 67 eyes (74%). At one year, follow-up information was available on 85 eyes of 85 patients. The average residual refractive error was -0.15 ± 0.65 diopters (range, -2.50 to +1.63 diopters). Correction within 1 diopter of that attempted was attained in 85 eyes (93%). Uncorrected visual acuity was 20/40 or better in 83 eyes (98%) and was 20/25 or better in 68 eyes (80%). One patient lost three lines of best-corrected visual acuity because of corneal haze, dropping from 20/15 to 20/30, whereas all other patients returned to best-corrected visual acuity within one line of their preoperative best-corrected visual acuity. Photorefractive keratectomy with the 193-nm excimer laser appears to be a useful treatment modality for the reduction of mild to moderate myopia.
Original language | English (US) |
---|---|
Pages (from-to) | 304-311 |
Number of pages | 8 |
Journal | American journal of ophthalmology |
Volume | 118 |
Issue number | 3 |
DOIs | |
State | Published - 1994 |
Funding
From the Phillips Eye Institute Center for Teaching and Research (Drs. Talley, Hardten, Sher, Kim, Doughman, Carpel, Ostrov, Lane, and Lindstrom and Ms. Parker), and Department of Ophthalmology, University of Minnesota, Minneapolis, Minnesota (Drs. Talley, Hardten, Sher, Doughman, Carpel, Lane, and Lind-strom); and St. Paul Ramsey Medical Center and Ramsey Clinic, St. Paul, Minnesota (Drs. Hardten and Lind-strom). This study was supported in part by a grant from VISX Company, Sunnyvale, California; by Health One Corporation, Minneapolis, Minnesota; and by the Friends of Phillips Foundation, Minneapolis, Minnesota. Dr. Sher owns stock in VISX Company, which was purchased on the open market, and has been a paid consultant for VISX.
ASJC Scopus subject areas
- Ophthalmology